Madrigal Pharmaceuticals (MDGL) Change in Acquisitions & Divestments (2011 - 2026)

Madrigal Pharmaceuticals (MDGL) has 16 years of Change in Acquisitions & Divestments data on file, last reported at $353.9 million in Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $353.9 million, up 20.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 17.13% YoY), and the FY2025 annual result was $1.1 billion, up 25.49% from the prior year.
• Change in Acquisitions & Divestments improved to $353.9 million in Q1 2026 per MDGL's latest filing, from $240.1 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $353.9 million in Q1 2026 and troughed at $12.0 million in Q1 2023.
• A 5-year average of $175.5 million and a median of $163.8 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2023 and 2024: Change in Acquisitions & Divestments plunged 87.18% in 2023, then jumped 1422.61% in 2024.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $79.2 million in 2022, then soared by 43.69% to $113.8 million in 2023, then soared by 165.75% to $302.4 million in 2024, then retreated by 20.59% to $240.1 million in 2025, then surged by 47.36% to $353.9 million in 2026.
• Business Quant data shows MDGL's Change in Acquisitions & Divestments at $353.9 million in Q1 2026, $240.1 million in Q4 2025, and $275.1 million in Q3 2025.